Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Key facts

Sponsor

Children's Oncology Group

Principal Investigator

Yael Mosse, M.D

Children's Oncology Group

Intervention

Alisertib(drug)

Enrollment

118 enrolled

Eligibility

1-21 years · All sexes

Timeline

2011 – 2019

Study locations (30)

• Children's Hospital of Alabama, Birmingham, Alabama, United States
• University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
• University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Southern California Permanente Medical Group, Downey, California, United States
• Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
• Children's Hospital Los Angeles, Los Angeles, California, United States
• Cedars-Sinai Medical Center, Los Angeles, California, United States
• Children's Hospital Central California, Madera, California, United States
• Children's Hospital of Orange County, Orange, California, United States
• Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
• Rady Children's Hospital - San Diego, San Diego, California, United States
• UCSF Medical Center-Parnassus, San Francisco, California, United States
• Connecticut Children's Medical Center, Hartford, Connecticut, United States
• Yale University, New Haven, Connecticut, United States
• Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT07549321
  A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
  Renaissance Pharma Ltd.
• RECRUITINGPHASE1, PHASE2NCT06625190
  Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
  University of Florida
• RECRUITINGPHASE1NCT07172958
  Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
  Children's National Research Institute
• RECRUITINGPHASE2NCT07085338
  A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
  St. Jude Children's Research Hospital
• RECRUITINGPHASE1, PHASE2NCT07399821
  An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
  Princess Maxima Center for Pediatric Oncology
• RECRUITINGPHASE1NCT06995872
  Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT06814496
  Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
  University of Arizona
• RECRUITINGPHASE1NCT07087002
  GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
  Stanford University

See all trials for Neuroblastoma →